1. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T (2011) PLoS One 6(4): e18462
    › Primary publication · 21541016 (PubMed) · PMC3081810 (PubMed Central)
  2. Race, kidney disease progression, and mortality risk in HIV-infected persons. Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA (2010) Clin J Am Soc Nephrol 5(12): 2269-75
    › Primary publication · 20876679 (PubMed) · PMC2994089 (PubMed Central)
  3. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR (2010) AIDS Patient Care STDS 24(5): 279-86
    › Primary publication · 20438375 (PubMed) · PMC2875979 (PubMed Central)
  4. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR (2010) Epidemiology 21(5): 698-705
    › Primary publication · 20585252 (PubMed) · PMC3086582 (PubMed Central)
  5. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T, AIDS Clinical Trials Group Study 384 Team, New Work Concept Sheet 273 Team (2010) J Infect Dis 201(11): 1703-7
    › Primary publication · 20402593 (PubMed) · PMC2862090 (PubMed Central)
  6. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP (2009) J Infect Dis 199(7): 991-8
    › Primary publication · 19220139 (PubMed) · PMC7822728 (PubMed Central)
  7. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Kallianpur AR, Hulgan T (2009) Pharmacogenomics 10(4): 623-37
    › Primary publication · 19374518 (PubMed) · PMC2706211 (PubMed Central)
  8. Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. Hulgan T, Donahue JP, Smeaton L, Pu M, Wang H, Lederman MM, Smith K, Valdez H, Pilcher C, Haas DW, AIDS Clinical Trials Group Study A5138 Team (2009) Eur J Clin Pharmacol 65(11): 1081-8
    › Primary publication · 19779705 (PubMed) · PMC2873632 (PubMed Central)
  9. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T (2009) J Acquir Immune Defic Syndr 52(4): 480-7
    › Primary publication · 19911471 (PubMed) · PMC2794651 (PubMed Central)
  10. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T (2009) J Clin Epidemiol 62(7): 729-37
    › Primary publication · 19108987 (PubMed) · PMC2747519 (PubMed Central)